ArticleBlood2013
Cytomegalovirus-specific T cells are primed early after cord blood transplant but fail to control virus in vivo.
Article in Blood, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 41 citations in OpenAlex.
- Trial
- Article
- CMV infection combined with acute GVHD associated with poor CD8+ T-cell immune reconstitution and poor prognosis post-HLA-matched allo-HSCT.Clinical and experimental immunology · 2022Article
- The generation and application of antigen-specific T cell therapies for cancer and viral-associated disease.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Review
- CMV Infection in Hematopoietic Stem Cell Transplantation: Prevention and Treatment Strategies.Current treatment options in infectious diseases · 2021Review
- Impact of HLA class I allele-level mismatch on viral infection within 100 days after cord blood transplantation.Scientific reports · 2020Article
- Robust CD4+ T-cell recovery in adults transplanted with cord blood and no antithymocyte globulin.Blood advances · 2020Article
- Cytomegalovirus-Mediated T Cell Receptor Repertoire Perturbation Is Present in Early Life.Frontiers in immunology · 2020Article
- Clinical Relevance of Immunobiology in Umbilical Cord Blood Transplantation.Journal of clinical medicine · 2019Review
- Therapeutic advantages provided by banked virus-specific T-cells of defined HLA-restriction.Bone marrow transplantation · 2019Review
- Major TCR Repertoire Perturbation by Immunodominant HLA-BFrontiers in immunology · 2018Article
- Observational
- Reconstitution of adaptive immunity after umbilical cord blood transplantation: impact on infectious complications.Stem cell investigation · 2017Review
- Virus-specific T-cell banks for 'off the shelf' adoptive therapy of refractory infections.Bone marrow transplantation · 2016Review
- Impact of early CMV reactivation in cord blood stem cell recipients in the current era.Bone marrow transplantation · 2016Article
- Incidence, nature and mortality of cytomegalovirus infection after double-unit cord blood transplant.Leukemia & lymphoma · 2015Article
- Engineered dendritic cells from cord blood and adult blood accelerate effector T cell immune reconstitution against HCMV.Molecular therapy. Methods & clinical development · 2015Article
- The role of the thymus in T-cell immune reconstitution after umbilical cord blood transplantation.Blood · 2014Review
- Improving engraftment and immune reconstitution in umbilical cord blood transplantation.Frontiers in immunology · 2014Review
- Diagnosis and treatment of viral diseases in recipients of allogeneic hematopoietic stem cell transplantation.Journal of hematology & oncology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
A disadvantage of umbilical cord blood transplantation (UCBT) is the delay in immune reconstitution, placing patients at increased risk for infections after transplant. Cytomegalovirus (CMV) in particular has been shown to cause significant morbidity in patients undergoing UCBT. Here, we comprehensively evaluate the development of CD4(+) and CD8(+) T-cell responses to CMV in a cohort of patients that underwent double UCBT. Our findings demonstrate conclusively that a diverse polyclonal CMV-specific T-cell response derived from the UCB graft is primed to viral antigens as early as day 42 after UCBT, but these T cells fail to achieve sufficient numbers in vivo to control CMV reactivations. This is not due to an inherent inability of UCB-derived T cells to proliferate, as these T cells underwent rapid proliferation in vitro. The TCR diversity and antigen specificity of CMV-specific T cells remained remarkably stable in the first year after transplant, suggesting that later control of virus replication results from improved function of T cells primed early after transplant and not from de novo responses derived from later thymic emigrants. Ex vivo expansion and adoptive transfer of CMV-specific T cells isolated from UCBT recipients early after transplant could augment immunity to CMV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.